Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.
RET-altered Non Small Cell Lung Cancer|RET-altered Solid Tumors
DRUG: TAS0953/HM06|DRUG: TAS0953/HM06
Phase 1 (dose-escalation): Maximum Tolerated Dose (MTD), Incidence rate and category of dose limiting toxicities (DLTs), At the end of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-expansion): Recommended Phase 2 dose (RP2D), At the end of Cycle 1 (each cycle is 21 days), and at the end of every subsequent cycle (each cycle is 21 days) for approximately 10 months (or earlier if patient discontinues the study)|Phase 2: Objective Response Rate (ORR) by independent central review, Proportion of patients with confirmed complete response (CR) and or partial response (PR) according to RECIST 1.1 as assessed by independent central review, Approximately every 6 weeks for 6 months, then every 9 weeks during treatment, 7 days after the last dose, and every 3 months after the last dose (up to an average of 2 years) in patients without progressive disease.
Phase 1 (dose expansion): Objective Response Rate (ORR) by independent central review, Proportion of patients with confirmed complete response (CR) and or partial response (PR) according to RECIST 1.1 as assessed by independent central review, Approximately every 6 weeks for 6 months, then every 9 weeks during treatment, 7 days after the last dose, and every 3 months after the last dose (up to an average of 2 years) in patients without progressive disease|Phase 2: ORR by Investigator, Proportion of patients with confirmed complete response (CR) and or partial response (PR) according to RECIST 1.1 as assessed by Investigator, Approximately every 6 weeks for 6 months, then every 9 weeks during treatment, 7 days after the last dose, and every 3 months after the last dose (up to an average of 2 years) in patients without progressive disease|Phase 2: Disease Control Rate (DCR), Proportion of patients with confirmed complete response (CR), partial response (PR) and Stable Disease according to RECIST 1.1 as assessed by Investigator, Approximately every 6 weeks for 6 months, then every 9 weeks during treatment, 7 days after the last dose, and every 3 months after the last dose (up to an average of 2 years) in patients without progressive disease|Phase 2: Time to Tumor Response (TTR), Time from first dose to first documentation of objective tumor response (CR or PR), From date of randomization until the date of first documentation of objective tumor response, assessed up to an average of 2 years.|Phase 2: Progression Free Survival (PFS), Time from first dose to first documentation of objective disease progression or to death due to any cause, whichever occurs first, From date of randomization until the date of first documented progression or death due to any cause, whichever occurs first, assessed up to an average of 2 years.|Phase 2: Time to Progression (TTP), Time from first dose to objective tumor progression, From date of randomization until the date of first documented progression, assessed up to an average of 2 years|Phase 2: Duration of Response (DOR), Time from first documentation of tumor response (CR + PR) to disease progression or death due any cause whichever occurs first, From first documentation of objective tumor response (CR or PR) until the date of first documented progression or death due to any causes, whichever occurs first, assessed up to an average of 2 years|Phase 2: Overall Survival (OS), Time from first dose to date of death due to any cause, From date of randomization until the date of death due to any cause, assessed up to an average of 2 years|Phase 2: Central Nervous System (CNS) ORR (C-ORR), Rate of confirmed CR and PR relative to patients with brain lesions at study entry, Approximately every 6 weeks for 6 months, then every 9 weeks during treatment, 7 days after the last dose, and every 3 months after the last dose (up to an average of 2 years) in patients without progressive disease|Phase 2: Central Nervous System DOR (C-DOR), Time from documentation of intracranial tumor response to disease progression or death due to any cause whichever occurs first, From first documentation of objective tumor response (CR or PR) until the date of first documented progression or death due to any causes, whichever occurs first, assessed up to an average of 2 years|Phase 2: Time to CNS progression, Time from the first dose to the first radiological evidence of CNS disease progression, From date of randomization until the date of first documented progression, assessed up to an average of 2 years|Phase 1 (dose-escalation): Area under the plasma concentration versus time curve from time 0 to 12 hours (AUC0-12), Day -1 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-escalation): AUC0-24, Day -1 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-escalation): AUC0-infinity, Day -1 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-escalation): AUC0-12 at steady state, Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-escalation): Maximum drug concentration (Cmax), Day -1 and Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-escalation): Trough drug concentration at 12 hours (Ctrough), Day -1 and Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-escalation): Time to maximum plasma concentration (tmax), Day -1 and Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-escalation): Terminal half-life (t1/2), Day -1 and Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-escalation): Accumulation factor based on Cmax (Rmax), Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-escalation): Accumulation factor based on Ctrough (Rmin), Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-escalation): Terminal rate constant (lambda_z), Day -1 and Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-escalation): Volume of Distribution (Vz/F), Day -1 and Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-escalation): Systemic clearance (CL/F), Day -1 and Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-escalation): Amount excreted in 0-24 hour urine (Ae0-24), Day -1 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-escalation): Renal Clearance (CL_R), Day -1 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-expansion): AUC0-12 at steady state, Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-expansion): Maximum drug concentration (Cmax), Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-expansion): Trough drug concentration at 12 hours (Ctrough), Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-expansion): Time to maximum plasma concentration (tmax), Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-expansion): Terminal rate constant (lambda_z), Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1 (dose-expansion): Terminal half-life (t1/2), Day 15 of Cycle 1 (each cycle is 21 days)|Phase 2 Population PK: Typical value of absorption rate constant (Ka), Day 15 of Cycle 1 (each cycle is 21 days)|Phase 2 Population PK: Typical value of CL/F, Day 15 of Cycle 1 (each cycle is 21 days)|Phase 2 Population PK: Typical value of volume of distribution (V/F), Day 15 of Cycle 1 (each cycle is 21 days)|Phase 1: Incidence of abnormal electrocardiograms (ECG QT interval). QT will be corrected for heart rate (QTc) using Fridericia's formula (QTcF)., On Day 1, Day 8 (only in dose escalation), Day 15 in cycle 1, Day 1 of any subsequent cycles (each cycle is 21 days) during treatment, for approximately 10 months (or earlier if the patient discontinues from the study), and 7 days after last dose|Phase 1: Incidence of treatment-emergent adverse events (TEAEs), From the time of informed consent, for approximately 10 months (or earlier if the patient discontinues from the study), and through Safety Follow-up (28 days after the last dose)|Phase 1: Incidence of serious adverse events (SAEs), From the time of informed consent, for approximately 10 months (or earlier if the patient discontinues from the study), and through Safety Follow-up (28 days after the last dose)|Phase 2: Incidence of abnormal electrocardiograms (ECG QT interval). QT will be corrected for heart rate (QTc) using Fridericia's formula (QTcF)., On Day 1 and Day 15 in cycle 1, Day 1 of any subsequent cycles (each cycle is 21 days) during treatment, for approximately 2 years (or earlier if the patient discontinues from the study), and 7 days after last dose|Phase 2: Incidence of treatment-emergent adverse events (TEAEs), From the time of informed consent for approximately 2 years (or earlier if the patient discontinues from the study), and through Safety Follow-up (28 days after the last dose)|Phase 2: Incidence of serious adverse events (SAEs), From the time of informed consent for approximately 2 years (or earlier if the patient discontinues from the study), and through Safety Follow-up (28 days after the last dose)
Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.